AD (SORL1) | |||||||
---|---|---|---|---|---|---|---|
Control | FTLD | AD (SORL1 WT) | AD (SORL1 nTD) | AD (SORL1 TD) | AD (SORL1 nTD + TD) | ||
N | 30 | 34 | 40 | 31 | 16 | 47 | |
Age at LP | years, mean (min-max) | 63 (40–75) | 65 (45–77) | 63 (51–76) | 65 (52–76) | 61 (46–69) | 64 (46–76) |
AAO | years, mean (min-max) | 60 (48–72) | 60 (49–73) | 57 (44–65) | 59 (44–73) | ||
Time AA0-LP | years, mean (min-max) | 3.9 (0.6–13.9) | 4.7 (0.3–10.1) | 3.7 (1.3–9.8) | 4.4 (0.3–10.1) | ||
Gender | Male N (%) | 15 (50.00%) | 18 (52.94%) | 16 (40.00%) | 9 (29.03%) | 6 (37.50) | 15 (31.91 %) |
Female N (%) | 15 (50.00%) | 16 (47.06%) | 24 (60.00%) | 22 (70.97%) | 10 (62.50) | 32 (68.09%) | |
APOE | ε2/ε2 N (%) | 0 | 0 | 0 | 0 | ||
ε2/ε3 N (%) | 1 (2.50%) | 1 (3.23%) | 0 | 1 (2.13%) | |||
ε2/ε4 N (%) | 0 | 2 (6.45%) | 0 | 2 (4.25%) | |||
ε3/ε3 N (%) | 16 (40.00%) | 9 (29.03%) | 8 (50.00%) | 17 (36.17%) | |||
ε3/ε4 N (%) | 16 (40.00%) | 15 (48.39%) | 7 (43.75%) | 22 (46.81%) | |||
ε4/ε4 N (%) | 7 (17.50%) | 4 (12.90%) | 1 (6.25%) | 5 (10.64%) |